Robert A. Belderbos

High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients

Luca Cantini, Federica Pecci, Daan P. Hurkmans et al. · European Journal of Cancer · 2020 · 107 citations

High-intensity Statins, Medicine, Pharmacology +8

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

Alessio Cortellini, Marcello Tiseo, Giuseppe Luigi Banna et al. · Cancer Immunology Immunotherapy · 2020 · 87 citations · Full text

Advanced Nsclc, Oncology, First-line Pembrolizumab Effectiveness +6

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

Alessio Cortellini, Alex Friedlaender, Giuseppe Luigi Banna et al. · Clinical Lung Cancer · 2020 · 82 citations · Full text

Pd-l1 Expression, Clinical Epidemiology, Immunology +8

Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program

Luca Cantini, Robert A. Belderbos, Cornedine J. de Gooijer et al. · Translational Lung Cancer Research · 2020 · 40 citations · Full text

Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study

Job P. van Kooten, Robert A. Belderbos, Jan H. von der Thüsen et al. · Thorax · 2022 · 37 citations · Full text